Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
AssigneeIncellDx, Inc.
InventorsEdgar B. Francisco, Hallison Rodrigues, Amruta Pise, Bruce K. Patterson
Life of this patent
Estimating the term…
Abstract
Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.
Claims12
A method of identifying and treating a subject having a critical or severe form of a disease involving hypercytokinemia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising:
- (a) determining the level of CCL5/RANTES in a test sample obtained from a subject having a disease involving hypercytokinemia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and identifying the subject as having a critical or severe form of the disease based on an increase in the level of CCL5/RANTES in the test sample as compared to a healthy control,
- wherein an increase of at least 6-fold indicates the severe form of the disease and an increase of at least 60-fold indicates the critical form of the disease, and
- (b) administering to the subject leronlimab (PRO-140) to treat the subject for the critical or severe form of the disease involving hypercytokinemia caused by SARS-CoV-2.
Dependencies are inferred from the claim text.